[
    [
        {
            "time": "",
            "original_text": "药明康德、宁德时代之后，又一巨头迈瑞医疗冲刺A股",
            "features": {
                "keywords": [
                    "药明康德",
                    "宁德时代",
                    "迈瑞医疗",
                    "A股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医疗设备"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "药明康德、宁德时代之后，又一巨头迈瑞医疗冲刺A股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[天眼] 独角兽长飞光纤断向A股 H股3年涨6倍",
            "features": {
                "keywords": [
                    "长飞光纤",
                    "A股",
                    "H股",
                    "涨幅"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "通信",
                    "光纤"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[天眼] 独角兽长飞光纤断向A股 H股3年涨6倍",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[看好评级] 医药生物行业2018年中报业绩前瞻：医疗需求刚性 重点关注稳健成长和“流量入口”型公司",
            "features": {
                "keywords": [
                    "医药生物",
                    "中报业绩",
                    "医疗需求",
                    "稳健成长",
                    "流量入口"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[看好评级] 医药生物行业2018年中报业绩前瞻：医疗需求刚性 重点关注稳健成长和“流量入口”型公司",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[增持评级] 医药生物行业周报：市场或迎来中级反弹 防御为先医药为上",
            "features": {
                "keywords": [
                    "医药生物",
                    "市场反弹",
                    "防御",
                    "医药"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级] 医药生物行业周报：市场或迎来中级反弹 防御为先医药为上",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "新共响获千万级天使轮投资，要做制造业的“药明康德”",
            "features": {
                "keywords": [
                    "新共响",
                    "天使轮",
                    "制造业",
                    "药明康德"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制造业",
                    "医药服务"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "新共响获千万级天使轮投资，要做制造业的“药明康德”",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "“独角兽”药明康德欲开启“A+H”时代",
            "features": {
                "keywords": [
                    "独角兽",
                    "药明康德",
                    "A+H",
                    "上市"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "“独角兽”药明康德欲开启“A+H”时代",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]